Filtered By:
Management: Funding
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 120 results found since Jan 2013.
Healthcare IT Regulations – What Needs to Be Added and What Needs to Be Removed
There are a lot of rules and regulations in place in the world of healthcare. These are put into place in order to protect patients and organizations. However, the world of healthcare is constantly changing and evolving as we come up with new ideas and solutions. Have the regulations done the same though? Or are there areas that are missing regulations? Or are there areas in healthcare where past regulations are now too restrictive and are holding us back?
In search of answers to these questions, we reached out to our incredibly beautiful Healthcare IT Today Community to see what areas they would add, remove, or update re...
Source: EMR and HIPAA - September 19, 2023 Category: Information Technology Authors: Grayson Miller Tags: Administration Ambulatory C-Suite Leadership Health IT Company Healthcare IT Hospital - Health System LTPAC Regulations 1upHealth 4medica Amanda Heidemann Andrea Mazzoccoli Andrew Norden MD Bill Charnetski Cheryl Cheng Commur Source Type: blogs
Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study
Lancet Haematol. 2023 Sep 6:S2352-3026(23)00212-0. doi: 10.1016/S2352-3026(23)00212-0. Online ahead of print.ABSTRACTBACKGROUND: Second primary malignancies (SPMs) are known complications after chemotherapy, but the risk is not well characterised for patients with lymphoma treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the rate of SPMs in this population relative to matched control individuals from the general population.METHODS: In this retrospective, population-based cohort study, patients aged 18 years or older with an aggressive lymphoma who r...
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Trine Trab Joachim Baech Lasse Hjort Jakobsen Simon Husby Marianne Tang Severinsen Sandra Eloranta Jette S G ørløv Judit M J ørgensen Sif Gudbrandsdottir Thomas Stauffer Larsen Peter Brown Kirsten Gr ønbæk Karin E Smedby Tarec C El-Galaly Source Type: research
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial
Lancet Oncol. 2023 Aug 14:S1470-2045(23)00329-7. doi: 10.1016/S1470-2045(23)00329-7. Online ahead of print.ABSTRACTBACKGROUND: Cemiplimab provided significant survival benefit to patients with advanced non-small-cell lung cancer with PD-L1 tumour expression of at least 50% and no actionable biomarkers at 1-year follow-up. In this exploratory analysis, we provide outcomes after 35 months' follow-up and the effect of adding chemotherapy to cemiplimab at the time of disease progression.METHODS: EMPOWER-Lung 1 was a multicentre, open-label, randomised, phase 3 trial. We enrolled patients (aged ≥18 years) with histologically ...
Source: Cancer Control - August 17, 2023 Category: Cancer & Oncology Authors: Mustafa Özgüroğlu Saadettin Kilickap Ahmet Sezer Mahmut G ümüş Igor Bondarenko Miranda Gogishvili Marina Nechaeva Michael Schenker Irfan Cicin Gwo Fuang Ho Yaroslav Kulyaba Kasimova Zyuhal Roxana-Ioana Scheusan Marina Chiara Garassino Xuanyao He Man Source Type: research
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
This study aims to assess the preliminary anti-tumor activity and safety of sintilimab plus bevacizumab, oxaliplatin and capecitabine as a treatment option for patients with RAS-mutant MSS mCRC.METHODS: This study was an open-label, single-arm, phase II trial in China. Patients with unresectable, RAS-mutant and MSS metastatic colorectal adenocarcinoma received treatment by intravenous sintilimab (200 mg, day 1) plus bevacizumab (7.5 mg/kg, day 1), oxaliplatin (135 mg/m2, day 1) and oral capecitabine (1 g/m2, day 1-14) in each 21-day cycle. The primary endpoints included objective response rate (ORR) and adverse events. Bio...
Source: Cancer Control - August 9, 2023 Category: Cancer & Oncology Authors: Xuefeng Fang Ning Zhu Chenhan Zhong Liuhong Wang Jun Li Shanshan Weng Hanguang Hu Caixia Dong Dan Li Yongmao Song Dong Xu Jianwei Wang Lifeng Sun Jian Wang Zhanhuai Wang Hongfeng Cao Xiujun Liao Ningjuan Yu Qian Xiao Mi Mi Suzhan Zhang Kefeng Ding Ying Yu Source Type: research
Inhibition of checkpoint kinase prevents human oocyte apoptosis induced by chemotherapy and allows enhanced tumour chemotherapeutic efficacy
Hum Reprod. 2023 Jul 14:dead145. doi: 10.1093/humrep/dead145. Online ahead of print.ABSTRACTSTUDY QUESTION: Could inhibition of the checkpoint kinase (CHEK) pathway protect human oocytes and even enhance the anti-tumour effects, during chemotherapy?SUMMARY ANSWER: CHEK inhibitors prevented apoptosis of human oocytes induced by chemotherapy and even enhanced the anti-tumour effects.WHAT IS KNOWN ALREADY: CHEK inhibitors showed ovarian protective effects in mice during chemotherapy, while their role in human oocytes is unclear.STUDY DESIGN, SIZE, DURATION: This experimental study evaluated the ovarian reserve of young patien...
Source: Cancer Control - July 14, 2023 Category: Cancer & Oncology Authors: Meng Wu Liru Xue Ying Chen Weicheng Tang Yican Guo Jiaqiang Xiong Dan Chen Qingqing Zhu Fangfang Fu Shixuan Wang Source Type: research
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study
EClinicalMedicine. 2023 Jun 23;61:102043. doi: 10.1016/j.eclinm.2023.102043. eCollection 2023 Jul.ABSTRACTBACKGROUND: Treatment options for patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) are not clear after progression on previous treatment with PD-(L)1 inhibitor; critical gaps in evidence remain for such cases. Immunotherapy combined with antiangiogenic therapy has been reported to have synergistic antitumor activity. Therefore, we evaluated the efficacy and safety of camrelizumab plus famitinib in patients with RM-NPC who failed treatment with PD-1 inhibitor-containing regimens.METHODS: This multice...
Source: Cancer Control - July 7, 2023 Category: Cancer & Oncology Authors: Xi Ding Yi-Jun Hua Xiong Zou Xiao-Zhong Chen Xi-Mei Zhang Bei Xu Yan-Feng Ouyang Zi-Wei Tu Hui-Feng Li Chong-Yang Duan Wei-Jing Zhang Rui You You-Ping Liu Yong-Long Liu Qi Yang Pei-Yu Huang Shu-Ni Wang Jia Fan Ming-Yuan Chen Source Type: research
Fight Aging! Newsletter, June 12th 2023
In this study, we investigated the effect of NXP032 on neurovascular stabilization through the changes of PECAM-1, PDGFR-β, ZO-1, laminin, and glial cells involved in maintaining the integrity of the blood-brain barrier (BBB) in aged mice. NXP032 was orally administered daily for 8 weeks. Compared to young mice and NXP032-treated mice, 20-month-old mice displayed cognitive impairments in Y-maze and passive avoidance tests. NXP032 treatment contributed to reducing the BBB damage by attenuating the fragmentation of microvessels and reducing PDGFR-β, ZO-1, and laminin expression, thereby mitigating astrocytes and microglia ...
Source: Fight Aging! - June 11, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
This study is registered at ClinicalTrials.gov, NCT04003636.FINDINGS: Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance t...
Source: JOP - April 19, 2023 Category: Gastroenterology Authors: Robin Kate Kelley Makoto Ueno Changhoon Yoo Richard S Finn Junji Furuse Zhenggang Ren Thomas Yau Heinz-Josef Kl ümpen Stephen L Chan Masato Ozaka Chris Verslype Mohamed Bouattour Joon Oh Park Olga Barajas Uwe Pelzer Juan W Valle Li Yu Usha Malhotra Abby Source Type: research
